Archives
-
Escitalopram Workflows for Antidepressant Research
2026-09-09
Escitalopram provides a selective, concentration-defined tool for 5-HT reuptake inhibition, transporter pharmacology, and serotonergic signaling studies. This guide translates findings from an anxious-depression augmentation study into practical assay design, dose planning, and troubleshooting strategies.
-
PTT–CD47 Blockade in Oral Squamous Cell Carcinoma
2026-09-09
A 2026 study shows that photothermal therapy strengthens CD47 blockade in oral squamous cell carcinoma by supplying a calreticulin-dependent eat-me signal and improving macrophage access through extracellular-matrix remodeling. The findings provide a mechanistic framework for combining tumor-directed heating with macrophage-mediated immunotherapy while highlighting important requirements for experimental replication.
-
Gramine and the CUL3–MTDH Ferroptosis Axis
2026-09-08
Gramine is a mechanistically informative ferroptosis inducer for triple-negative breast cancer research. This article translates the CUL3–MTDH discovery into an evidence-centered framework for selecting controls, interpreting readouts, and handling the N2337 research compound.
-
ML385: Practical NRF2 Inhibition in Cell Assays
2026-09-08
ML385 (SKU B8300) is a selective NRF2 inhibitor for investigating oxidative stress, ferroptosis, cell viability, and cancer therapeutic resistance. This scenario-based guide connects product specifications and published NRF2 research with practical workflows for formulation, controls, interpretation, and vendor selection.
-
DAPI Nuclear Stain Solution: Practical Guide
2026-09-07
DAPI (4',6-Diamidino-2-Phenylindole) Nuclear Stain Solution provides a ready-to-use fluorescent DNA binding dye for nuclear visualization and endpoint assessment of membrane-compromised cells. It is suited to fixed or otherwise permeable samples analyzed by fluorescence microscopy or flow cytometry, but it should not be treated as a primary stain for routine imaging of intact live cells.
-
3-Dehydroteasterone Analogues in Brassinosteroid Research
2026-09-07
Valdés and colleagues developed benzoylated 3-dehydroteasterone analogues with a 23,24-dinorcholanic side chain and evaluated them in two plant-growth bioassays. The work shows that benzoate substitution, C-3 oxidation state, and assay choice strongly influence activity, with one ortho-acetoxy analogue approaching Brassinolide activity in the rice lamina inclination test.
-
MSC–NRF2–ATF4 Stress Signaling in PDAC
2026-09-05
A 2026 study shows that Se-methylselenocysteine produces phenotype-dependent NRF2 and ATF4 stress responses in pancreatic ductal adenocarcinoma, with KYAT1 expression helping determine cellular sensitivity. The findings connect redox and metabolic remodeling with ferroptosis-associated processes and provide a framework for testing redox vulnerabilities in pancreatic cancer.
-
Bazedoxifene and IL-6/GP130 Signaling in Cancer
2026-09-04
The 2024 review by Shi and colleagues examines bazedoxifene as a repurposing candidate that can interfere with IL-6/GP130 signaling, a pathway linked to tumor survival, proliferation, inflammation, and therapeutic resistance. Its synthesis of computational, mechanistic, and preclinical evidence clarifies why this approved osteoporosis drug merits further oncology investigation while also highlighting the substantial validation still needed before clinical repositioning.
-
ML385: Practical NRF2 Inhibition Workflows
2026-09-04
ML385 is a selective NRF2 inhibitor for dissecting antioxidant signaling, cancer therapeutic resistance, and stress-response phenotypes. This guide translates its use into practical dose–time experiments, orthogonal target-engagement assays, combination studies, and troubleshooting workflows.
-
HyperTrap Heparin HP Column: Lab Scenarios
2026-09-03
This scenario-driven guide explains how HyperTrap Heparin HP Column (SKU PC1009) can standardize upstream protein purification for cell viability, proliferation, and cytotoxicity studies. It connects column chemistry, operating limits, protocol choices, and data interpretation to practical decisions made at the bench.
-
Alosetron and Intestinal Polarity Research
2026-09-03
Alosetron is best known as a selective 5-HT3 receptor antagonist for gastrointestinal research, but its strategic value may extend to mechanistic studies of epithelial renewal. This article connects serotonin receptor pharmacology with the CDC42–YAP/TAZ–EGF–mTOR framework governing intestinal stem cell and transit-amplifying cell balance. Rather than overstate an unproven connection, it outlines a disciplined experimental path for testing whether 5-HT3 receptor signaling intersects epithelial polarity, gastrointestinal motility modulation, and visceral pain signaling research.
-
Boc-D-FMK: Causal Analysis of Apoptosis Signals
2026-09-02
Boc-D-FMK is a cell-permeable pan-caspase inhibitor for separating caspase-dependent death from inflammatory and fibrosis-associated readouts. This guide connects mechanistic controls with insights from a hepatic stellate cell study to improve assay interpretation across renal and hepatic models.
-
β-Amanitin: A Mechanistic Probe for RNA Polymerase II
2026-09-02
β-Amanitin is more than a transcription inhibitor: it is a controlled perturbation tool for connecting RNA polymerase II activity with assay design. This article explains how beta-amanitin supports mechanistic studies, how recent amatoxin biosensing advances affect experimental decisions, and how to interpret results responsibly.
-
Quercetin PI3K Inhibitor: Applied Research Workflows
2026-09-01
Build reproducible Quercetin assays that connect PI3K signaling, mitochondrial apoptosis, and ferroptosis rather than relying on a single endpoint. This workflow translates recent liver-injury findings into practical cancer research, oxidative-stress, and pathway-validation experiments.
-
ML385: Practical NRF2 Inhibition Workflows
2026-09-01
ML385 enables controlled NRF2 signaling pathway inhibition in cancer-cell, oxidative-stress, and therapeutic-resistance studies. This workflow-oriented guide shows how to connect target engagement with ferroptosis-related readouts while avoiding common dosing, vehicle, and interpretation errors.